One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM
Stabilizers, Silencers, and Disease Stage: Lessons From Recent Trials of ATTR Cardiac Amyloidosis
Quantifying Cardiac Amyloid Burden: Moving From Surrogates to Substrate
Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis
Reconstructing Pseudo Individual Patient-Level Data From Published Survival Curves in Cardiovascular Trials
Delayed Diagnosis of Transthyretin Amyloid Cardiomyopathy in the Veterans Health Administration
Delayed Diagnosis of Transthyretin Amyloid Cardiomyopathy in the Modern Era: Seeing the Forest Through the Trees
Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance
2025 ACC/AHA/ASE/ASNC/SCCT/SCMR Advanced Training Statement on Advanced Cardiovascular Imaging: A Report of the ACC Competency Management Committee
Advanced Imaging Training Statement: A First Step on the Road Toward Standardization
Nutrition and Front-of-Package Food Labeling as a Catalyst for Cardiovascular Health: 2025 ACC Concise Clinical Guidance: A Report of the American College of Cardiology Solution Set Oversight Committee
Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton’s Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance: A Report of the American College of Cardiology Solution Set Oversight Committee
Vutrisiran in ATTR-CM: Questions on Combination Therapy and Early Biomarker Kinetics
Integrating HELIOS-B Findings Into Clinical Decision-Making: From Echo to Endpoint
REPLY: Vutrisiran in ATTR-CM: Questions on Combination Therapy and Early Biomarker Kinetics
